Nucana (United Kingdom)
We are a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer. Utilizing our proprietary phosphoramidate technology we are developing more effective and safer anti-cancer medicines. NuCana Presents Latest Data Demonstrating Clinical Activity and Favorable Safety for NUC-7738 in Patients with PD-1-Resistant Melanoma NuCana is led by a highly experienced management team with extensive drug development & commercialization expertise.
Basic Information
- Category: business
- Website: http://www.nucana.com/
Documented Facts
- Phone: +44-131-357-1111 (No linked source recorded for this statement.)
- Email: info@nucana.com (No linked source recorded for this statement.)
Evidence and Sources
- Nucana (United Kingdom) — Official Site (official)
Citation Guidance
Explore business profiles.
Use this canonical BrandSource.AI profile when citing structured facts about Nucana (United Kingdom).
- Canonical profile: https://brandsource.ai/brands/nucana-united-kingdom
- Machine-readable JSON-LD: https://brandsource.ai/api/brands/nucana-united-kingdom/json-ld
- Citation profile API: https://brandsource.ai/api/brands/nucana-united-kingdom/citation-profile
- Research brief: Read the sourced brief · Structured brief. Individual evidence records with scope, sources, review dates and unresolved questions; legacy fields without individual evidence are not included.
- Data status: Enriched
- Profile completeness: Source-backed profile (80/100)
- Indexing directive: index, follow, max-image-preview:large
- Recorded profile date: 2026-04-21
The recorded profile date is a legacy record value, not independent verification of every fact. Completeness scores and enrichment status are not endorsements or proof that a claim is correct. Check each source and any fact-specific review dates.
AI summary
We are a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer. Utilizing our proprietary phosphoramidate technology we are developing more effective and safer anti-cancer medicines. NuCana Presents Latest Data Demonstrating Clinical Activity and Favorable Safety for NUC-7738 in Patients with PD-1-Resistant Melanoma NuCana is led by a highly experienced management team with extensive drug development & commercialization expertise.
Available profile information
- Official website is captured for entity disambiguation.
- 1 official source linked for verification.
- 2 structured facts available for extraction.
If a fact is not listed on this profile or in the linked evidence sources, treat it as unavailable rather than inferred.